| Ytd | -3.55% | |
| 1y | 14.10% |
| Open | 19.01 | Prev Close | 19.21 | Low | 18.81 | High | 19.17 | Mkt Cap | 852.45M |
| Vol | 301.89K | Avg Vol | 554.31K | EPS | -0.33 | P/E | N/A | Forward P/E | -17.55 |
| Beta | 1.23 | Short Ratio | 2.47 | Inst. Own | 99.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 17.85 | 200-d Avg | 16.37 | 1yr Est | 22.78 |
SIBN News
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global lead
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out
The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While
The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical res
SiBone (NASDAQ: SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
Si-Bone (SIBN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate
SiBone NASDAQ: SIBN reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss a
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark
SI-BONE (NASDAQ:SIBN) raises FY2026 sales outlook from $230.000 million-$233.000 million to $231.000
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.09) per share which beat the analyst consensu
Delivered ~15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physi
UBS analyst Patrick Wood initiates coverage on SI-BONE (NASDAQ:SIBN) with a Buy rating and announ
SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global lead
Truist Securities analyst Richard Newitter maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global lead
Si-Bone (SIBN) witnesses a hammer chart pattern, indicating support found by the stock after losing
The average of price targets set by Wall Street analysts indicates a potential upside of 71.1% in Si
Gazprom Neft , the oil arm of Russia's energy giant Gazprom , said on Friday its first-quarter
The consensus price target hints at a 65.3% upside potential for Si-Bone (SIBN). While empirical res
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-ex
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and lowers
Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising gui
SiBone NASDAQ: SIBN raised its full-year 2026 outlook after reporting double-digit revenue growth in
Si-Bone (SIBN) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate
SI-BONE (NASDAQ:SIBN) raises FY2026 sales outlook from $228.500 million-$232.500 million to $230.000
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.10) per share which beat the analyst consensu
Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjust
Truist Securities analyst Samuel Brodovsky maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.04) per share which beat the analyst consensu
TD Cowen analyst Mathew Blackman initiates coverage on SI-BONE (NASDAQ:SIBN) with a Buy rating an
SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinic
SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax
Truist Securities analyst David Rescott maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the
Canaccord Genuity analyst Caitlin Roberts maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises t
Needham analyst David Saxon maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price targe